Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NS-7 (Nippon Shinyaku).

D L Small1

  • 1National Research Council of Canada, Receptors and Ion Channels Group, Institute for Biological Sciences, Building M-54, Montreal Road, Ottawa, ON K1A 0R6, Canada. Dan.Small@nrc.ca

Idrugs : the Investigational Drugs Journal
|August 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An alternative splicing variant in Clcn7-/- mice prevents osteopetrosis but not neural and retinal degeneration.

Veterinary pathology·2010
Same author

Refractive-Index Measurements of Undoped Yttrium Aluminum Garnet from 0.4 to 5.0 mum.

Applied optics·2008
Same author

Ion channels involved in stroke.

Expert opinion on therapeutic targets·2005
Same author

Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block.

The Journal of pharmacology and experimental therapeutics·2001
Same author

Characterization of cyclin D1 expression in a rat global model of cerebral ischemia.

Brain research·2001
Same author

Animal models.

British medical bulletin·2000
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Nippon Shinyaku is developing NS-7, a novel neuroprotectant, for treating cerebral infarction. This sodium and calcium channel blocker has advanced to Phase II clinical trials, with Schering leading development in Europe and the US.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cardiovascular Research

Background:

  • Cerebral infarction, a leading cause of disability, requires effective neuroprotective treatments.
  • Current therapeutic options for acute stroke are limited, highlighting the need for novel agents.
  • Sodium and calcium channel blockers show potential in mitigating neuronal damage post-ischemia.

Purpose of the Study:

  • To evaluate the neuroprotective potential of NS-7 in patients following cerebral infarction.
  • To assess the safety and efficacy of NS-7 in early-stage clinical trials.
  • To advance the development of NS-7 for acute stage cerebrovascular disorders.

Main Methods:

  • NS-7, a sodium and calcium channel blocker, is undergoing clinical development.

Related Experiment Videos

  • Phase I trials were initiated in 1997 for acute cerebrovascular disorders.
  • Phase II studies were planned in Japan as of November 1999.

    • Main Results:

    • NS-7 has successfully progressed through Phase I clinical trials.
    • Preparations for Phase II studies in Japan were underway by November 1999.
    • Development rights were granted to Schering, indicating promising preclinical and early clinical data.

    Conclusions:

    • NS-7 demonstrates potential as a neuroprotectant for cerebral infarction.
    • The drug's development is advancing, with international collaboration for further trials.
    • Further clinical evaluation by Schering in Europe and the US is anticipated.